Last reviewed · How we verify
Heliox21 — Competitive Intelligence Brief
marketed
Respiratory gas mixture
Respiratory
Small molecule
Live · refreshed every 30 min
Target snapshot
Heliox21 (Heliox21) — University College, London. Heliox21 is a mixture of helium and oxygen used to reduce the work of breathing in patients with respiratory distress.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Heliox21 TARGET | Heliox21 | University College, London | marketed | Respiratory gas mixture |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Respiratory gas mixture class)
- University College, London · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Heliox21 CI watch — RSS
- Heliox21 CI watch — Atom
- Heliox21 CI watch — JSON
- Heliox21 alone — RSS
- Whole Respiratory gas mixture class — RSS
Cite this brief
Drug Landscape (2026). Heliox21 — Competitive Intelligence Brief. https://druglandscape.com/ci/heliox21. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab